Shape Memory Medical Inc., a Santa Clara, Calif.-based developer of custom shape memory polymers for endovascular markets, completed a $38m Series C financing.

位于加利福尼亚州圣克拉拉的形状记忆医学公司（Shape Memory Medical Inc.）为血管内市场开发定制形状记忆聚合物，完成了3800万美元的C系列融资。

The round was led by Earlybird Venture Capital with participation from new and existing investors including HBM Healthcare Investments (Cayman) Ltd., WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P. Thom Rasche, Partner at Earlybird Venture Capital, joined the Shape Memory Medical Board.

这一轮由Earlybird Venture Capital牵头，新的和现有的投资者参与，包括HBM Healthcare Investments（Cayman）Ltd.，WexMed II LLC，HBM Medfocus LLC和Emergent Medical Partners II，Earlybird Venture Capital合伙人L.P.Thom Rasche加入了形状记忆医学委员会。

The company intends to use the funds to accelerate the clinical and market development of shape memory polymer technology for aortic and peripheral vascular markets. The funds will support the execution of the AAA-SHAPE Pivotal Trial, a randomized controlled study comparing EVAR plus sac management with IMPEDE-FX RapidFill to stand-alone EVAR.

该公司打算利用这些资金加速形状记忆聚合物技术在主动脉和外周血管市场的临床和市场开发。这些资金将支持AAA-SHAPE Pivotal试验的实施，该试验是一项随机对照研究，将EVAR加sac管理与Endobate-FX RapidFill与独立EVAR进行比较。

The funding will also support the research and development of our product pipeline, and the expansion of sales and marketing strategies to address the increasing demand for the company’s commercially-available IMPEDE Embolization Plug family of devices.

这笔资金还将支持我们产品线的研究和开发，以及扩大销售和营销策略，以满足对该公司商业上可获得的阻碍栓塞插头系列设备日益增长的需求。

Led by Ted Ruppel, president and CEO, Shape Memory Medical is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers, with devices approved in more than 25 countries spanning regions in Asia, the Middle East, Europe, the Americas and Australia. Neurovascular embolization products include the TrelliX® Embolic Coil, which is CE marked for use in the EU.

在总裁兼首席执行官特德·鲁佩尔（Ted Ruppel）的带领下，形状记忆医学致力于开发具有专有形状记忆聚合物的创新治疗解决方案，该设备已在亚洲、中东、欧洲、美洲和澳大利亚等25个国家获得批准。神经血管栓塞产品包括TrelliX®栓塞线圈，该线圈被CE标记用于欧盟。

Peripheral embolization products include the IMPEDE® and IMPEDE-FX Embolization Plugs and IMPEDE-FX RapidFill® Device. In countries recognizing CE marking, the IMPEDE and IMPEDE-FX Embolization Plugs and the IMPEDE-FX RapidFill are indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature.

外围栓塞产品包括ENABRED®和ENABRED-FX栓塞塞和ENABRED-FX RapidFill®设备。在认识到CE标记的国家，指示阻碍和阻碍-FX栓塞塞和阻碍-FX快速填充物阻碍或降低外周脉管系统的血流速度。

In the United States, the IMPEDE Embolization Plug is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, and the IMPEDE-FX Embolization Plug is indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature.

在美国，阻碍栓塞塞被指示阻碍或降低外周脉管系统中的血流速度，而阻碍-FX栓塞塞被指示与阻碍栓塞塞一起使用以阻碍或降低外周脉管系统中的血流速度。

The IMPEDE and IMPEDE-FX Embolization Plugs are PMDA approved in Japan. Caution: IMPEDE-FX RapidFill is an investigational device, limited by Federal (or United States) law to investigational use.

Bounder和Bounder-FX栓塞塞在日本获得PMDA批准。注意：阻碍-FX RapidFill是一种研究设备，受联邦（或美国）法律限制用于研究。